ASAM is committed to improving access to high-quality, evidence-based addiction prevention and treatment through our national advocacy efforts.

National Advocacy

Working closely with lawmakers on Capitol Hill and leaders in the Administration, we advocate for policies that promote a stronger addiction treatment workforce, standardize the delivery of individualized addiction treatment, and ensure equitable access and coverage for comprehensive, high-quality addiction care.

advocacy-webpage-graphics-teach-it

TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma.

0. Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of individualized addiction treatment so that more patients receive high-quality, evidence-based care.
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to comprehensive, high-quality addiction care.
s1
Other Policy Areas include a wide range prevention efforts and research of substance-related problems.

UTSAM Opposes Legislation Establishing New Medical Cannabis Provider Type

by | Feb 12, 2021

 

On February 12, the Utah Society of Addiction Medicine (UTSAM) submitted a letter in opposition to SB170, which would establish a new provider type under Utah’s medical cannabis law. Currently only qualified medical providers may recommend medical cannabis to a patient. Qualified medical providers are clinicians who must satisfy an array of conditions including licensure under the state's controlled substances law, and receiving continuing medical education (CME) on recommending cannabis. Furthermore, qualified medical providers may not to own, or be employed by, a cannabis production establishment, a medical cannabis pharmacy, or a medical cannabis courier.

 

SB170 would create a new provider type, called “limited medical provider.” This provider type would also be a clinician licensed under the state's controlled substances law. However, this provider type would not be required to complete the CME on recommending cannabis, and furthermore, would be allowed to own, or be employed by, a cannabis production establishment, a medical cannabis pharmacy, or a medical cannabis courier. These limited medical providers would only be able to recommend cannabis to up to 15 patients. UTSAM’s letter focused on the importance of ensuring that clinicians recommending medical cannabis are sufficiently educated on the drug before they recommend it. Furthermore, it noted that cannabis is associated with a myriad of health risks, and has not been approved by the Food and Drug Administration for any medical indication. 

 

Read the letter here.

 

Read the bill here

 

Subscribe to the ASAM Advocate

Your source for timely, useful news briefings of top stories in addiction policy.